Gunnarsson, N
Höglund, M
Stenke, L
Wållberg-Jonsson, S
Sandin, F
Björkholm, M
Dreimane, A
Lambe, M
Markevärn, B
Olsson-Strömberg, U
Wadenvik, H
Richter, J
Själander, A
Article History
Received: 22 November 2015
Revised: 11 February 2016
Accepted: 19 February 2016
First Online: 8 March 2016
Competing interests
: AS had a consulting role for ARIAD. JR has received honoraria from ARIAD, Bristol-Myers Squibb and Novartis. MB have a consulting role for Roche, Tolero Pharmaceuticals and Nordic Nanovector, and received honoraria from Roche, Tolero Pharmaceuticals and Nordic Nanovector. ML have stock ownership in AstraZeneca and Pfizer. SW-J received honoraria from MDS. MH has a consulting role for Akinion Pharmaceuticals and has received honoraria from Janssen-Cilag. The remaining authors declare no competing financial interests.